Risk Assessment and Minimization for Progressive Multifocal Leukoencephalopathy (PML RAMP): A Program to Assess for Potential Early Signs and Symptoms of PML during Clinical Development of Vedolizumab

被引：4

作者：

Clifford, David ^{[1
]}

McAuliffe, Megan ^{[2
]}

Stephens, Kristin ^{[2
]}

Major, Eugene ^{[3
]}

Fox, Irving ^{[2
]}

Milch, Catherine ^{[4
]}

Sankoh, Serap ^{[2
]}

Provenzale, James ^{[4
]}

Lev, Michael ^{[5
]}

Freedland, Eric ^{[2
]}

Berger, Joseph ^{[6
]}

Parikh, Asit ^{[7
]}

机构：

[1] Washington Univ, Sch Med, St Louis, MO USA

[2] Millennium Pharmaceut Inc, Cambridge, MA USA

[3] NINDS, NIH, Bethesda, MD 20892 USA

[4] Duke Univ, Med Ctr, Durham, NC USA

[5] Massachusetts Gen Hosp, Boston, MA 02114 USA

[6] Univ Kentucky, Lexington, KY USA

[7] Takeda Pharmaceut Int Inc, Deerfield, IL USA

来源：

关键词：

D O I：

10.14309/00000434-201310001-01673

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1673

引用

页码：S502 / S502

页数：1